Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Phase 2 N=21 Cabozantinib and Pembrolizumab in Metastatic Pancreas
Pancreatic Cancer
Primary: Progression-free Survival — 2 Participants
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Phase 2 N=72 Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months
Phase 2 N=42 Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Primary: 12- Month Overall Survival (OS) — 16 Participants
Phase 2 N=50 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Metastatic Pancreatic Cancer
Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months
Phase 2 N=25 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 2 N=23 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants
Phase 2 N=25 Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Stage IV Pancreatic Cancer
Primary: Complete Response Rate — 2; 15; 4; 3 Participants
Phase 2 N=48 Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Pancreatic Cancer · Periampullary Adenocarcinoma
Primary: Late Gastrointestinal Toxicities — 13 Participants
Phase 2 N=48 ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Phase 2 N=8 AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pancreatic Neoplasms
Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026
Phase 2 N=273 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
N/A N=36 Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
Pancreatic Neoplasms
Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants
Phase 2 N=53 Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
Pancreatic Adenocarcinoma
Primary: Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 subjects
Phase 2 N=60 Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Pancreatic Cancer
Primary: Overall Survival — 24.8 Months
Phase 2 N=11 A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…
Phase 2 N=33 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Phase 2 N=27 MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants
Phase 2 N=16 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
Pancreatic Cancer · Pancreatic Ductal Adenocarcinoma · Pancreatic Adenocarcinoma
Primary: Best Overall Response (BOR) — 0; 0; 3; 11 Participants
Phase 2 N=104 Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 4.2; 8.3 months — p=0.36
Phase 3 N=211 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival — 6.4; 5.9 months
Phase 2 N=83 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 9.38; 14.7 Months
Phase 2 N=44 Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer Metastatic
Primary: Progression Free Survival (PFS) — 4 months
Phase 2 N=40 Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Maximum Tolerated Dose (MTD) of Epacadostat — 600 mg BID
Phase 2 N=67 Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants
Phase 2 N=54 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Phase 3 N=200 Standardization of Surgery on the Pancreatic Cancer
Pancreatic Cancer
Primary: Survival — 37; 31 participants